Trump, Interest Rates, And Biotech Investing In 2017

December 23, 2016

We are heading into 2017 with a great deal of uncertainty, but if President-elect Trump governs the nation as he said he would – unconventionally and unpredictably – we may experience a significant uptick in market volatility as foreign governments and global markets react to America’s new stance in the world.

Continue Reading

Siemens And Northwell Announce Alliance, Enter Big Data Arms Race

December 1, 2016

In an era where a doctor’s office can generate a terabyte of data easily and toasters can speak to refrigerators, we are in an unprecedented age of information and connectivity.

Continue Reading

After Lilly Bombs, Could Alzheimer’s Become Healthcare’s Trumpshot?

November 30, 2016

If the healthcare industry’s approach to Alzheimer’s disease were a building project, it could best be described as constructing a skyscraper from the top down–possible, yet at best impractical.

Continue Reading

5 Healthcare Questions That Should (But Won’t) Be Asked At The Debate

October 7, 2016

As the election draws closer, issue polls consistently rank health care affordability at or near the top of American voters’ concerns.

Continue Reading

WBB Securities Acts as Co-Manager for $300 Million Public Offering for Sarepta Therapeutics

September 29, 2016

WBB Securities acted as co-manager to a transaction for Sarepta Therapeutics, Inc., a developer of innovative RNA-targeted therapeutics.

Continue Reading

John Nolan Joins WBB to Head Asset Management Team

September 2, 2016

WBB Securities, a leading investment management, investment banking, and equity research firm, announced today that John Nolan has joined the firm as Managing Director of WBB Asset Management[1] where he will also serve as a Portfolio Manager of a concentrated long/short portfolio that focuses on the biotechnology, specialty pharmaceutical and medical device sectors.

Continue Reading

WBB Securities Sponsors BioCentury’s Annual NewsMakers Conference

September 1, 2016

WBB Securities is a sponsor of this year’s NewsMakers in the Biotech Industry conference.

Continue Reading

How Mylan And Pfizer Could Cause A Major Biotech Backlash

August 25, 2016

You know you’re in the middle of a crisis when Martin Shkreli defends your pharmaceutical company’s price hikes.

Continue Reading

Brexit Will Be Bad For Pharma

June 25, 2016

In medicine they talk about triage in making quick decisions to save lives. Central bankers and politicians across Europe will be performing financial triage this weekend on the UK and EU.

Continue Reading

Superbug Hearing: Will Congress Pick Up Ali’s Fight Against Sepsis?

June 14, 2016

During his life, Muhammad Ali did many great things for a great many people. But he may still have another contribution to make to the public, or in this case, for the public’s health.

Continue Reading